Dazucorilant for ALS patients at higher risk of faster progression
Treatments studied
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This Phase 2 study tests whether dazucorilant can slow or improve outcomes in people with amyotrophic lateral sclerosis (ALS) who are likely to progress more quickly. You may be able to join if you meet specific ALS type and risk-score requirements and your health tests and medications fit the study rules.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 18 or older and have sporadic or familial ALS
- Meet the study’s specific ALS “risk of progression” score range (different for Part 1 vs Part 2)
- If you take riluzole, edaravone, and/or sodium phenylbutyrate and taurursodiol, you must be on a stable dose before screening
- If you are in Part 2: you must not be using tofersen (or be eligible to use it) if you have an SOD1 gene mutation
- Be able to swallow capsules and have blood tests showing platelets at least 150,000/mm³
- Have kidney function with eGFR above 30; no recent kidney injury unless it has returned to your usual baseline
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called VTx-002 to see if it is safe and tolerable for people with ALS. You may be able to join if you have had symptoms for less than 18 months and have a caregiver who can help.
This trial is testing if an oral medication called pridopidine can slow the progression of ALS. It is for people recently diagnosed with ALS who have mild to moderate breathing function and meet specific risk scores.
This trial tests whether adding two supplements (EH-301 and N-acetylcysteine) to the standard ALS medicine Riluzole can help slow the disease. It is for people diagnosed with ALS within the last 18 months who still have good breathing and daily function.
This study tests a supplement called acetyl-L-carnitine (ALCAR) to see if it can slow the progression of ALS. It is for people in the early stages of the disease who are already taking riluzole and have good lung and muscle function.
This Phase 2 study tests tideglusib to see if it helps slow or improve amyotrophic lateral sclerosis (ALS). You may be eligible if you have early-stage ALS with preserved breathing ability and certain stable treatments.
This trial tests whether a drug called tazbentetol can help people with ALS. It aims to see if it is safe and slows the disease's progression.
Hear when a new Amyotrophic Lateral Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.